Table 1.
Characteristics of participants at cohort entry overall and stratified by the presence or absence of an episode of AKI during follow-up
| Characteristics of participants | Total, n=2048 | AKI during Follow-Up, n=324 | Non-AKI during Follow-Up, n=1724 | P Value |
|---|---|---|---|---|
| Characteristics at cohort entry | ||||
| Age at cohort entry, mean (±SD), yr | 63.3 (±12.4) | 63.9 (±11.6) | 63.2 (±12.5) | 0.35 |
| Women, N (%) | 900 (43.9%) | 145 (44.8%) | 755 (43.8%) | 0.75 |
| Black race, N (%) | 361 (17.6%) | 59 (18.2%) | 302 (17.5%) | 0.76 |
| eGFR at cohort entry, ml/min per 1.73 m2 | ||||
| Median [interquartile range] | 62.9 [46.9–84.6] | 57.1 [43.8–81.0] | 63.9 [48.3–85.1] | <0.01 |
| Urine protein-to-creatinine ratio at cohort entry (g/g) | ||||
| Median [interquartile range] | 0.12 [0.07–0.25] | 0.17 [0.09–0.42] | 0.11 [0.07–0.23] | <0.001 |
| Diabetes mellitus, N (%) | 805 (39.3) | 186 (57.4) | 619 (35.9) | <0.001 |
| Use of ACE-I or ARB at cohort entry, N (%) | 989 (48.3) | 175 (54.0) | 814 (47.2) | <0.05 |
| No. of BP medications at cohort entry | ||||
| Median [interquartile range] | 2 [1–2] | 2 [1–3] | 2 [1–2] | <0.001 |
| Systolic BP at cohort entry, mm Hg | ||||
| Mean (±SD) | 126 (±21) | 129 (±23) | 126 (±21) | <0.05 |
| Diastolic BP at cohort entry, mm Hg | ||||
| Mean (±SD) | 71 (±14) | 71 (±14) | 71 (±13) | 0.87 |
| Follow-up characteristics | ||||
| Follow-up time (year) | ||||
| Median [interquartile range] | 3.9 [2.0–5.8] | 4.0 [2.8–5.7] | 3.9 [1.9–5.8] | 0.12 |
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.